Active Filters
- Press ReleaseClear filter
![S1801 Melanoma Results at ESMO 2022](/sites/default/files/styles/news_recent/public/news/2022-09/press-release-card-S1801-ESMO22.png?itok=LbJEHe_q)
Sep 11, 2022
SWOG researchers have found that starting pembrolizumab before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma.
![S0931 EVEREST results at ASCO 2022](/sites/default/files/styles/news_recent/public/news/2022-06/Press.Card_.S0931.jpg?itok=-K_3LFAG)
Jun 3, 2022
S0931 found everolimus after surgery tended to increase recurrence-free survival time in patients with high-risk kidney cancer, although results narrowly missed reaching statistical significance
![Lung-MAP S1800A results at ASCO 2022](/sites/default/files/styles/news_recent/public/news/2022-06/Press.Card_.S1800A.jpg?itok=rZ5iky-i)
Jun 3, 2022
Ramucirumab plus pembrolizumab combination reduced risk of death by 31 percent compared to standard of care in patients with advanced non-small cell lung cancer that had progressed on prior immunotherapy.
![ACA Medicaid Expansion and SWOG Trial Participants](/sites/default/files/styles/news_recent/public/news/2022-06/Press.Card_.Medicaid2.jpg?itok=V3YDpu_o)
Jun 1, 2022
Affordable Care Act’s expansion of Medicaid in 2014 was followed by a significant rise in proportion of enrollees in group’s cancer trials insured by Medicaid.
![Using cfDNA to predict bladder cancer chemo benefit](/sites/default/files/styles/news_recent/public/news/2022-05/S1314.ASCO_.png?itok=2sppyG0i)
May 26, 2022
SWOG researchers have used methylation patterns in cell-free DNA from blood samples to predict which patients with muscle-invasive bladder cancer are likely to benefit from neoadjuvant chemo and which patients can safely skip it.
![Standing CSF orders had limited impact](/sites/default/files/styles/news_recent/public/news/2022-05/S1415CD.ASCO%20copy_0.png?itok=gieypRuK)
May 26, 2022
Adding standing physician orders to electronic record systems did not improve adherence to guidelines for prophylactic prescribing of colony-stimulating factors for febrile neutropenia for patients on high-risk or low-risk chemotherapy.
![Desmoplastic melanoma responds to PD-1 blockade](/sites/default/files/styles/news_recent/public/news/2022-05/S1512.ASCO_.png?itok=Og4NoJEh)
May 26, 2022
A high rate of response to neoadjuvant PD-1 blockade in patients with desmoplastic melanoma suggests such therapy could reduce the extent of surgery needed on the face and neck.